ArticleBMC oral health2026
Identification of oral squamous cell carcinoma by an electronic nose based on an array of metal oxide sensors with machine learning.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) presents a significant diagnostic challenge due to the lack of specific early-stage symptoms, in which the rapid, non-invasive tools are urgently needed. However, the utility of electronic nose (eNose) technology as an adjunct diagnostic aid remains to be validated under standardized sampling conditions.
methodsWe performed a diagnostic study to evaluate whether a portable "PEN3" equipped with 10 metal oxide sensors (eNose) could identify OSCC patients. We analyzed aspirated air samples from OSCC patients (n = 98) and healthy controls (n = 76) using the eNose, with histopathological diagnosis serving as the reference standard. To analyze eNose signals, we adopted a dual-branch modeling strategy: five data-driven machine learning classifiers enhanced by Kernel Principal Component Analysis (KPCA), and a Weighted Least Absolute Shrinkage and Selection Operator (Lasso) model designed to incorporate clinical prior knowledge.
resultsAnalysis of 174 breath samples revealed that standard machine learning models (specifically SVM) could distinguish OSCC with an AUC exceeding 94%. Crucially, the Physiologically-Weighted Lasso model achieved comparable robust performance (AUC = 91.71%, Sensitivity = 90.13%) without relying on complex non-linear manifolds. We found that Physiologically-Weighted Lasso model achieved more stabilized result comparing the unweighted model. Moreover, SHapley Additive exPlanations (SHAP) confirmed that the model (alcohols, carbonyls, organic sulfides, and alkanes) effectively prioritized sensors responsive to organic sulfides.
conclusionsWe developed a promising eNose-based diagnostic model that effectively balances high diagnostic accuracy with clinical interpretability. The validation of the Physiologically-Weighted Lasso model indicates distinct gas metabolite patterns for OSCC, suggesting that the device detects a genuine pathological metabolic shift driven by organic volatiles rather than stochastic noise. This provides a transparent and potential adjunct tool for non-invasive OSCC screening.
trial registrationChinese Clinical Trial Registry, ChiCTR2500102625. Registered 16 May 2025—Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.